CTAD 2026

Hendrix et al

 

Projections Confirm Long-Term Benefits of Continuous Lecanemab: 10 Years of Treatment Could Delay Moderate Disease by 18.7 Years

Copies of these presentations obtained through the QR code are for personal use only and may not be used without permission from CTAD and the authors of this presentation.